Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

McGill University

$382,500.00

Microfiltration of Circulating and Disseminated Tumor Cells in Ovarian Cancer: From Monitoring Therapeutic Response Towards Predicting Disease Outcome

EF 2017-18

Résumé
Circulating and disseminated tumor cells (CTCs, DTCs) that dissociate from the primary tumor, can be found, respectively, in blood and ascites of ovarian cancer patients, and could be used to monitor the response to therapy, and help track the tumor state. CTCs and DTCs are very rare and present in low numbers, and isolating them has been a great challenge and has prevented using them more broadly for cancer disease management. As CTC isolation technologies have progressed, subpopulations of CTCs with various metastatic potentials have been identified. Very recently, aggregates of CTCs, callled CTC clusters, have been discovered, and they were found to have an approx. 50 times higher metastatic potential. Our team developed a microfiltration system which we believe outperforms other CTC isolation systems as when we analyzed a small ovarian cancer patient cohort in a pilot study, we observed CTCs and clusters in every patient, whereas previously they were only rarely found. Our method is also simple to use, potentially low cost if mass produced, and hence could be adopted for clinical use in the future. Here, we propose to use our microfiltration system to monitor the response to therapy in ovarian cancer patients by taking blood and ascites before surgery, after surgery, and at different time points during chemotherapy. We will isolate CTCs, DTCs and clusters, and analyze the number of cells and clusters, their morphology, and different molecular markers that are expressed and which have been linked to cancer metastasis and resistance to therapy. This study will validate our technology in a clinical context, and provide insight into the mechanisms of tumor response and resistance to therapy in ovarian cancer. It will set the foundation for future studies to help stratify patients and establish disease prognostics, and perhaps identify groups that might benefit from targeted, precision therapies, both for ovarian and other cancers.
Programme
Project Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
382636
Name
Juncker David
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Biomedical Engineering
Projecttitle
Microfiltration of Circulating and Disseminated Tumor Cells in Ovarian Cancer: From Monitoring Therapeutic Response Towards Predicting Disease Outcome
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$382,500
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Biomedical Device; Cancer Dissemination; Circulating Tumor Cell (Ctc); Ctc Cluster; Ctc Enrichment; Epithelial Ovarian Cancer; Gravity-Driven Filtration; Metastasis; Microfilters; Prognosis
Abstract
Circulating and disseminated tumor cells (CTCs, DTCs) that dissociate from the primary tumor, can be found, respectively, in blood and ascites of ovarian cancer patients, and could be used to monitor the response to therapy, and help track the tumor state. CTCs and DTCs are very rare and present in low numbers, and isolating them has been a great challenge and has prevented using them more broadly for cancer disease management. As CTC isolation technologies have progressed, subpopulations of CTCs with various metastatic potentials have been identified. Very recently, aggregates of CTCs, callled CTC clusters, have been discovered, and they were found to have an approx. 50 times higher metastatic potential. Our team developed a microfiltration system which we believe outperforms other CTC isolation systems as when we analyzed a small ovarian cancer patient cohort in a pilot study, we observed CTCs and clusters in every patient, whereas previously they were only rarely found. Our method is also simple to use, potentially low cost if mass produced, and hence could be adopted for clinical use in the future. Here, we propose to use our microfiltration system to monitor the response to therapy in ovarian cancer patients by taking blood and ascites before surgery, after surgery, and at different time points during chemotherapy. We will isolate CTCs, DTCs and clusters, and analyze the number of cells and clusters, their morphology, and different molecular markers that are expressed and which have been linked to cancer metastasis and resistance to therapy. This study will validate our technology in a clinical context, and provide insight into the mechanisms of tumor response and resistance to therapy in ovarian cancer. It will set the foundation for future studies to help stratify patients and establish disease prognostics, and perhaps identify groups that might benefit from targeted, precision therapies, both for ovarian and other cancers.
Competitiondate
201803
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Juncker, David
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $382,500~ $0~